The FDA has approved Trogarzo (ibalizumab-uiyk), from Theratechnologies, as medication for adult patients living with HIV who have tried multiple...
Theratechnologies Inc. announced that the FDA has approved the company’s Labelling Prior Approval Supplement to include a 2000-mg intravenous (IV) push loading dose for Trogarzo (ibalizumab-uiyk)
Theratechnologies Inc. a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced that the Company has filed a supplemental Biologics License Application (sBLA) for an intramuscular (IM) method of administration for the maintenance dose of Trogarzo (ibalizumab-uiyk) to the FDA for review
Theratechnologies Inc. is pleased to announce that results from the phase III clinical trial used to obtain FDA approval for...
Trogarzo, in combination with other antiretroviral(s), is indicated for the treatment of adults infected with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive antiviral regimen (see section 5.1).